VEGFA and neoplasm: Examples include the epidermal growth factor receptor tyrosine kinase inhibitor cetuximab,8 vascular endothelial growth factor (VEGF) inhibitors bevacizumab9 and ramucirumab,10 and multi‐target anti‐tumour drugs sorafenib11 and sunitinib.12